Research shows that intensified systemic therapy for metastatic renal cell carcinoma (mRCC) has improved patient outcomes, focusing on local control of metastases through various ablative therapies.*
-
A systematic review identified 18 studies on metastasis-directed therapies, predominantly stereotactic body radiotherapy (SBRT), which showed a local control rate of 84.4% at 12 months and a median overall survival of 22.7 months for patients.*
-
While SBRT demonstrated excellent local control with manageable toxicity, only a few studies on thermal ablation therapies were found, indicating a need for more comprehensive research in this area.*
The treatment of liver-limited oligometastatic disease aims for a potentially curative outcome, especially in cases that were previously deemed unresectable due to advancements in chemotherapy and biologics.
Interventional techniques like portal vein embolization and innovative liver-directed ablative therapies, alongside advanced radiotherapy options, offer new potential for converting unresectable tumors into resectable ones.
A multidisciplinary approach is essential for integrating these various treatment modalities to improve patient outcomes in metastatic colorectal cancer.